Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-20

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

High blood pressure can cause physical changes to the blood vessels of the body (remodeling). If a person who has high blood pressure also has a lot of blood vessel remodeling with their condition, they are more likely to have poor results with medical treatment for hypertension. The researchers examine the impact of different classes of drugs that doctors use to treat high blood pressure (hypertension) on blood vessel remodeling. Some drugs that doctors prescribe for their patients contain a "sulfhydryl group" (a sulfur atom bonded to a hydrogen atom). Drugs that have the sulfhydryl group may reduce blood vessel remodeling more that drugs that do not. For this study, participants who have high blood pressure perform the experiments, take a drug for 16-weeks to lower blood pressure, and repeat the experiments. The researchers randomly assign one of three drugs to participants who have high blood pressure: a diuretic ("water pill"), a drug containing a sulfhydryl (SH) group, or a drug that does not contain a sulfhydryl group. Participants who do not have high blood pressure perform the experiments, but do not take any of the drugs. In some of our experiments, the researchers use a technique called "microdialysis" (MD). With MD, the researchers perfuse some research drugs into the skin on the forearm through tiny tubing that mimics capillaries. These MD drugs mimic or block substances the body naturally makes to control the small blood vessels in the skin. The drugs remain in nickel-sized areas around the tubing and do not go into the rest of the body. The researchers also analyze very small skin samples (skin biopsy) obtained from the forearm. Lastly, the researchers use a standard technique called "flow mediated dilation" (FMD) that uses blood pressure cuffs and ultrasound to look at the health of larger blood vessels in the body. FMD includes placing a small tablet of nitroglycerin under the tongue during part of the test.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

NCT03738878

Hypertension

TERMINATED PHASE4

Genetic Mechanisms in Human Hypertension

NCT01456208

Hypertension

TERMINATED

Targeting Endoplasmic Reticulum Stress in Human Hypertension

NCT06025630

Hypertension

RECRUITING PHASE1/PHASE2

Vascular Dysfunction in Hypertensive Postmenopausal Women

NCT03371823

Cardiovascular Diseases Hypertension

TERMINATED PHASE4

Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function

NCT01822860

Hypertension

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Upon initial screening and again within a week of testing, all subjects will have an assessment of 24-hour ambulatory blood pressure. Subject screening will be performed by the Penn State Clinical Translational Research Center (CTRC) medical staff and will include a physical exam by a clinician, anthropometry, and a chemical and lipid profile, liver and renal function. Women will be either postmenopausal (absence of menstruation of \>1 year and Follicle Stimulating Hormone (FSH) \>25 milli-international units per milliliter (mlU/ml)) and not be taking hormone replacement therapy, or normally menstruating and tested in the early follicular phase of their cycle. Subjects will also go through an assessment of conduit vessel endothelial and vascular smooth muscle function with brachial artery flow-mediated vasodilation (FMD), and sublingual nitroglycerin.

Subjects will undergo initial microdialysis experiments and biopsy samples will be obtained. Subjects will then be randomly assigned to treatment group. Blood pressure will be monitored every 2 weeks and weekly compliance checks will be made by the researcher's nurse coordinator. 24-hour ambulatory blood pressure monitoring will be conducted monthly to determine the efficacy of antihypertensive treatment and to inform dosing titration. Examining pharmacokinetic and dynamic data from the literature indicate that blood pressure lowing and peripheral vascular effects are maximized by 12 weeks of antihypertensive therapy and maintained thereafter. After 16 weeks of the assigned intervention, subjects will repeat microdialysis experiments and additional cutaneous biopsy samples will be obtained. Conduit artery measures including brachial artery FMD and responsiveness to sublingual nitroglycerin will also be evaluated at this time.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension,Essential

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Subjects are grouped as normal (\<120/80 mmHg) and hypertensive (≥140/90 mmHg and \<160/110 mmHg). All subjects undergo one round of experiments. Hypertensive subjects received randomly-assigned antihypertension medication angiotensin converting enzyme inhibitor with a sulfahydrl donor (ACEi+SH), angiotensin converting enzyme inhibitor (ACEi), or diuretic for 16 weeks and then repeat experiments. Normotensive subjects receive no intervention and repeat experiments16 weeks after initial experiments as a time control.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Investigator and Outcomes Assessor are masked according to treatment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normotensive

Blood Pressure \<120/80 mmHg

Group Type NO_INTERVENTION

No interventions assigned to this group

Hypertensive - ACE inhibitor with sulfahydrl donor (ACEi +SH)

Captopril Pill intervention Blood Pressure ≥140/90 mmHg and \<160/110 mmHg

Group Type EXPERIMENTAL

Captopril Pill

Intervention Type DRUG

ACEi+SH

Hypertensive - ACE inhibitor (ACEi)

Enalapril Pill intervention Blood Pressure ≥140/90 mmHg and \<160/110 mmHg

Group Type EXPERIMENTAL

Enalapril Pill

Intervention Type DRUG

ACEi

Hypertensive - Diuretic

Hydrochlorothiazide intervention Blood Pressure ≥140/90 mmHg and \<160/110 mmHg

Group Type ACTIVE_COMPARATOR

Hydrochlorothiazide

Intervention Type DRUG

diuretic

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Captopril Pill

ACEi+SH

Intervention Type DRUG

Enalapril Pill

ACEi

Intervention Type DRUG

Hydrochlorothiazide

diuretic

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

National Drug Code (NDC) # 00781-8061-01 NDC# 51672-4039-03 NDC# 00603-3857-32

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women and men
* 40-65 years
* Blood pressure: Normotensive \<120/80 mmHg Hypertensive ≥140/90 mmHg and \<160/110 mmHg
* HbA1C of \<6.5%
* Women are post-menopausal and not taking hormone replacement therapy, or have normal cycles and are tested in the early follicular phase
* Subjects may or may not be taking one doctor-prescribed drug to lower blood pressure (e.g. diuretic, ACE inhibitor).

* Must be able to stop physician-prescribed antihypertensive drug for the duration of the subject's participation in the study (with the approval of their personal physician).

Exclusion Criteria

Relevant to all subjects:

* current medications which could conceivably alter the cardiovascular or thermoregulatory control or responses (e.g. beta blockers, calcium channel blockers, ACE inhibitors, angiotensin receptor blockers)
* taking a diuretic (also see below)
* allergy to test substances
* allergy to latex
* nicotine use (smoking, chewing tobacco, etc.)
* illegal/recreational drug use
* pregnancy or breastfeeding
* diabetes

Relevant to hypertensive subjects only:

* contraindication for all three pharmacotherapy drugs used in this study

o Note: Subjects who have a contraindication (e.g. a condition, medication with a known interaction, known allergy) to only one or two of the three pharmacotherapy drugs, may be assigned one of the pharmacotherapy drugs that is not contraindicated.
* history of having taken an ACE inhibitor with antioxidant properties (e.g. Captopril, Zofenopril)
* kidney problems
* liver problems
* history of heart disease or failure
* history of blood clots or stroke
* angioedema
* electrolyte imbalance
* planned surgery requiring general anesthesia during the pharmacotherapy period
* peripheral vascular disease
* diuretics (a subject taking only a diuretic to control the subject's hypertension may be included in the study if the subject stops taking the diuretic for the duration of the subject's participation in the study with the approval of the subject's personal physician.)

Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes